AUTHORS
Ranjit Nair, MD, Sairah Ahmed, MD2, Luis E. Fayad, MD3, Luis Malpica, MD4, Sattva S Neelapu Sr, MD5, Jared Henderson, PhD6, Frederick B. Hagemeister, MD7, Chijioke C Nze, MD, MPH8, Fateeha Furqan, MBBS9, Paolo Strati, MD10, Ayushi Chauhan, MD11, Dai Chihara, MD, PhD12, Mark P Hamilton, MD13, Susana salazar Andrade De Jesus, RN, BSN14, Ana Koshy, MSN, AGACNP-BC15, Hongyan Wang, PA16, Janine Arafat, BA17, Hun Ju Lee, MD18, Swaminathan P. Iyer, MD19, Anath Christopher Lionel, MD, PhD20, Christopher R. Flowers Jr, MD, MS21, Michael Green, PhD22, Lei Feng, MS23, Jason Westin, MD, MS, FACP, FASCO24, Raphael Steiner, MD25
AFFILIATIONS
1 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Background
Primary mediastinal large B-cell lymphoma (PMBL) is a distinct subtype of aggressive B-cell lymphoma that predominantly affects young adults. Although DA-EPOCH-R achieves excellent cure rates, it requires prolonged inpatient infusional chemotherapy and is associated with acute and long-term toxicities. Strategies that reduce chemotherapy exposure while maintaining efficacy remain an important unmet need. PMBL shares biologic features with classical Hodgkin lymphoma, including frequent CD30 expression and alterations of the PD-1/PD-L1 axis, providing a strong rationale for incorporating brentuximab vedotin (BV) and nivolumab (Nivo) into frontline therapy. The investigator-initiated PACIFIC study evaluated a PET-guided, response-adapted strategy incorporating an immune lead-in with BV plus Nivo followed by BV/Nivo plus R-CHP in previously untreated PMBL.
Methods
PACIFIC (NCT04745949) is a, single-center, phase II study of adults with previously untreated stage I-IV PMBL. Patients receive two 21-day cycles of BV (1.8 mg/kg) plus nivolumab (240 mg; cycles 1–2), followed by two cycles of BV/Nivo plus R-CHP (cycles 3–4).
Patients achieving complete response (CR) at PET/CT before cycle 5 receive 2 more cycles of BV-Nivo+R-CHP (cycle 5 and 6) and BV-Nivo only for cycles 7 and 8. Patients with PR before cycle 5 will receive 4 more cycles of BV-Nivo+R-CHP (cycles 5-8).
Following a protocol amendment, patients requiring urgent cytoreduction could receive one cycle of standard of care chemoimmunotherapy before protocol therapy
The primary endpoint is CR at end of treatment (EOT). Secondary endpoints include progression-free survival (PFS), overall survival (OS), duration of response (DoR), safety and patient-reported outcomes. Exploratory correlative studies include longitudinal ctDNA analysis, with additional translational findings to be presented.
Results
As of the July 2026 data cutoff, 30 patients were enrolled. The median age was 39 years (range, 19–62), 56.7% female and Ann Arbor stage II, III, and IV disease was present in 15 (50.0%), 4 (13.3%), and 11 (36.7%) patients, respectively. Thirteen patients (43%) received one cycle of standard-of-care chemoimmunotherapy for urgent disease control before initiating protocol therapy.
Among 27 evaluable patients after the two cycles of immune lead in BV/Nivo, the overall response rate (ORR) was 59.3% (16/27; 95% CI, 38.8–77.6%) and CR rate was 48.1% (13/27; 95% CI, 28.7–68.1%). One patient who achieved CR after the immune lead-in withdrew consent before the scheduled cycle 4 PET assessment. Among the remaining 26 patients, including one who experienced disease progression before cycle 4 PET, the CR rate increased to 80.8% (21/26). These patients achieving a CR then transitioned to the protocol-defined response-adapted abbreviated treatment strategy consisting of two additional cycles of BV-Nivo+R-CHP followed by two cycles of BV/Nivo.
Among patients evaluable at the EOT, 25/26 (96%) achieved CR. With a median follow-up of 13.3 months (95% CI, 8.8–22.2), the estimated 12-month PFS rate was 96.4% (95% CI, 89.8–100%). Median PFS was not reached, with one progression event observed and no deaths to date.
Thirteen patients (43%) experienced at least one Grade ≥3 adverse event. The most common Grade ≥3 adverse events were elevated ALT (n=5), maculopapular rash (n=3), anemia (n=2), vomiting (n=2), and elevated AST (n=2). No grade 5 treatment-related adverse events were observed.
Three patients discontinued protocol therapy after infusion-related hypersensitivity reactions during the first cycle of BV/nivolumab and elected to continue treatment off protocol. One additional patient withdrew consent after achieving CR following the immune lead-in and remains in CR 30 months later without additional therapy.
Correlative analyses evaluating circulating tumor DNA (ctDNA) clearance and tumor microenvironment changes are ongoing.
Conclusions
A response-adapted frontline strategy incorporating an immune lead-in with BV/ Nivo followed by BV/Nivo+R-CHP demonstrated promising efficacy in newly diagnosed PMBL, achieving a high EOT CR rate, encouraging early PFS and a manageable safety profile. This response-adapted strategy demonstrates the feasibility of reducing anthracycline exposure to a cumulative doxorubicin dose of 200 mg/m² in patients achieving an early response. Ongoing follow-up and correlative ctDNA analyses will further characterize the long-term efficacy of this approach.
DISCLOSURES
Ranjit Nair, MD: No relevant conflicts of interest to declare.